Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

Table 2 Health state based utilities and costs used in the model

Health states	> 500	350–500	200–350	100–200	50–100	0–50
Utilities	0.896	0.899	0.886	0.861	0.843	0.822
Costs (RMB)
Outpatient care	1998	2356	2356	3072	4891	4891
Inpatient care	787	1019	1017	2317	9197	9075
AOI	27	17	18	84	84	201
OI prophylaxis	0	0	0	1	1	2
Cardiovascular event	11	14	17	17	17	17
Indirect costs	0	327	219	1274	1274	1.274

ISSN: 1478-7547